Related Experiment Video

Updated: Nov 22, 2025

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.4K

CD44 enhances adriamycin resistance in chronic myelogenous leukaemia cells K562

Juan Li1,2, Yanfang Zhang1,3, Yubo Cui1,4

  • 1Department of Internal Medicine, The Affiliated Hospital of Yanbian University, Yanji, China.

International Journal of Laboratory Hematology
|January 7, 2021
PubMed
Abstract

Insights

CD44 enhances adriamycin resistance in chronic myelogenous leukemia K562 cells by increasing proliferation and migration while decreasing apoptosis. This suggests CD44 regulates key proteins involved in chemoresistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Leukemia Research

Background:

  • Investigating the role of CD44 in adriamycin-resistant chronic myelogenous leukemia (CML) K562 cells.
  • Exploring CD44's influence on K562 cell migration and apoptosis.

Purpose of the Study:

  • To determine the functional impact of CD44 overexpression on adriamycin resistance in K562 cells.
  • To elucidate the molecular mechanisms by which CD44 affects chemoresistance, migration, and apoptosis.

Main Methods:

  • GeneChip® screening for chemoresistance-related gene expression in K562/ADR cells.
  • Generation of K562/CD44 cells via plasmid transfection.
  • Confirmation of adriamycin resistance by assessing migration and apoptosis-related protein and mRNA expression using Western blotting and Real-time PCR.

Main Results:

  • K562/CD44 cells exhibited high CD44 expression, increased mRNA levels of CD44 and P-glycoprotein (P-gp), and elevated proliferation rates.
  • Apoptosis rate was decreased in K562/CD44 cells, with upregulated migration proteins (MMP-2, MMP-9) and downregulated pro-apoptotic protein Bax.
  • Bcl-2 protein levels remained largely unchanged, indicating a complex regulation of apoptosis.

Conclusions:

  • CD44 plays a significant role in adriamycin resistance in CML K562 cells.
  • CD44 may mediate chemoresistance through the regulation of P-gp, MMP-2, MMP-9, and the Bcl-2/Bax apoptosis pathway.
Keywords:
ADRCD44apoptosisdrug resistanceleukaemia

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.4K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K